Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
- PMID: 22868819
- DOI: 10.1001/archinternmed.2012.3147
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
Abstract
BACKGROUND Treatment of hypertension in patients with diabetes mellitus (DM) has been shown to improve cardiovascular outcomes; however, the value of intensive blood pressure (BP) targets remains uncertain. We sought to determine the effectiveness and safety of treating BP to intensive targets (upper limit of 130 mm Hg systolic and 80 mm Hg diastolic) compared with standard targets (upper limit of 140-160 mm Hg systolic and 85-100 mm Hg diastolic) in patients with type 2 DM. METHODS Using electronic databases, bibliographies, and clinical trial registries, we conducted a systematic review and meta-analysis to identify randomized trials enrolling adults diagnosed as having type 2 DM and comparing prespecified BP targets. Data on study characteristics, risk for bias, and outcomes were collected. Random-effects models were used to pool relative risks and risk differences for mortality, myocardial infarction, and stroke. RESULTS The use of intensive BP targets was not associated with a significant decrease in the risk for mortality (relative risk difference, 0.76; 95% CI, 0.55-1.05) or myocardial infarction (relative risk difference, 0.93; 95% CI, 0.80-1.08) but was associated with a decrease in the risk for stroke (relative risk, 0.65; 95% CI, 0.48-0.86). The pooled analysis of risk differences associated with the use of intensive BP targets demonstrated a small absolute decrease in the risk for stroke (absolute risk difference, -0.01; 95% CI, -0.02 to -0.00) but no statistically significant difference in the risk for mortality or myocardial infarction. CONCLUSION Although the use of intensive compared with standard BP targets in patients with type 2 DM is associated with a small reduction in the risk for stroke, evidence does not show that intensive targets reduce the risk for mortality or myocardial infarction.
Comment in
-
Diabetes: no clear advantage for intensive blood pressure control in T2DM.Nat Rev Endocrinol. 2012 Nov;8(11):628. doi: 10.1038/nrendo.2012.158. Epub 2012 Aug 28. Nat Rev Endocrinol. 2012. PMID: 22926100 No abstract available.
-
ACP Journal Club. Review: Intensive blood pressure control reduces stroke, but not mortality or MI, in type 2 diabetes.Ann Intern Med. 2013 Jan 15;158(2):JC5. doi: 10.7326/0003-4819-158-2-201301150-02005. Ann Intern Med. 2013. PMID: 23318339 No abstract available.
-
Meta-analysis shows limited benefit of lowering blood pressure below 130/80 mm Hg in patients with type 2 diabetes.Evid Based Med. 2013 Dec;18(6):222-3. doi: 10.1136/eb-2013-101302. Epub 2013 May 3. Evid Based Med. 2013. PMID: 23645888 No abstract available.
Similar articles
-
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.Circulation. 2011 Jun 21;123(24):2799-810, 9 p following 810. doi: 10.1161/CIRCULATIONAHA.110.016337. Epub 2011 May 31. Circulation. 2011. PMID: 21632497
-
Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials.Heart. 2013 May;99(9):601-13. doi: 10.1136/heartjnl-2012-301968. Epub 2012 Aug 21. Heart. 2013. PMID: 22914531 Review.
-
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients.J Hypertens. 2011 Jul;29(7):1253-69. doi: 10.1097/HJH.0b013e3283469976. J Hypertens. 2011. PMID: 21505352
-
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.Am J Med. 2013 Jun;126(6):501-8. doi: 10.1016/j.amjmed.2013.01.007. Epub 2013 Mar 28. Am J Med. 2013. PMID: 23541376 Clinical Trial.
-
Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Am J Cardiovasc Drugs. 2012. PMID: 22217193 Review.
Cited by
-
Update on blood pressure control and renal outcomes in diabetes mellitus.Curr Diab Rep. 2015 Jul;15(7):44. doi: 10.1007/s11892-015-0613-6. Curr Diab Rep. 2015. PMID: 25990743 Review.
-
SPRINT to evidence for specific blood pressure targets.Can Fam Physician. 2016 Aug;62(8):638. Can Fam Physician. 2016. PMID: 27521391 Free PMC article. No abstract available.
-
Type 2 diabetes and cardiovascular disease: what next?Curr Opin Endocrinol Diabetes Obes. 2014 Apr;21(2):109-20. doi: 10.1097/MED.0000000000000044. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 24569552 Free PMC article. Review.
-
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.J Am Coll Cardiol. 2017 Aug 15;70(7):883-893. doi: 10.1016/j.jacc.2017.07.001. J Am Coll Cardiol. 2017. PMID: 28797359 Free PMC article. Review.
-
Comparison of treatment outcomes in patients with and without diabetes mellitus attending a multidisciplinary cardiovascular prevention programme (a retrospective analysis of the EUROACTION trial).BMC Cardiovasc Disord. 2015 Feb 24;15:11. doi: 10.1186/s12872-015-0006-4. BMC Cardiovasc Disord. 2015. PMID: 25887559 Free PMC article.
LinkOut - more resources
Full Text Sources